Codon usage in paillomavirus genes: Practical and functional aspects

Papillomavirus Report

Volumn 16, Issue 2, 2005, Pages 63-72

  Bravo, Ignacio G ^a   Müller, Martin ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE GAMMA; GREEN FLUORESCENT PROTEIN; PROTEIN E6; PROTEIN E7; STRUCTURAL PROTEIN; TRANSFER RNA; VIRUS PROTEIN;

CELLULAR DISTRIBUTION; CODON USAGE; ESCHERICHIA COLI; EXPRESSION VECTOR; GC RICH SEQUENCE; GENE TRANSFER; GENETIC ANALYSIS; GENETIC TRANSFECTION; NONHUMAN; PAPILLOMA VIRUS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RNA TRANSLATION; SACCHAROMYCES CEREVISIAE; SCHIZOSACCHAROMYCES POMBE; SEMLIKI FOREST ALPHAVIRUS; STOP CODON; VACCINIA VIRUS; VIRAL GENETICS; VIRUS CAPSID;

ALPHAVIRUS; ESCHERICHIA COLI; MIRIDAE; PAPILLOMAVIRUS; SACCHAROMYCES CEREVISIAE; SCHIZOSACCHAROMYCES POMBE; SEMLIKI FOREST VIRUS; VACCINIA; VACCINIA VIRUS;

EID: 18044391460     PISSN: 09574190     EISSN: None     Source Type: Journal    
DOI: 10.1179/095741905X24996     Document Type: Review

References (56)

1. Knight RD, Freeland SJ, Landweber LF. A simple model based on mutation and selection explains trends in codon and amino-acid usage and GC composition within and across genomes. Genome Biol 2001;2:10.1-13.
2. Bulmer M. Coevolution of codon usage and transfer RNA abundance. Nature 1987;325:728-30.
3. Gustafsson C, Govindarajan S, Minshull K. Codon bias and heterologous protein expression. Trends Biotechnol 2004;22:346-53.
4. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6:315-24.
5. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996;70:4646-54.
6. Bradel-Tretheway BG, Zhen Z, Dewhurst S. Effects of codon-optimization on protein expression by the human herpesvirus 6 and 7 U51 open reading frame. J Virol Methods 2003;111:145-56.
7. Gao F, Li Y, Decker JM, Peyerl FW, Bibollet-Ruche F, Rodenburg CM et al. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res Hum Retroviruses 2003;19:817-23.
8. zur Megede J, Otten GR, Doe B, Liu H, Leung L, Ulmer JB et al. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines. J Virol 2003;77:6197-207.
9. Sharma OK, Borek E. A mechanism of estrogen action on gene expression at the level of translation. Cancer Res 1976;36:4320-9.
10. Sharma OK, Kuchino Y. Infidelity of translation of encephalomyocarditis viral RNA with tRNA from human malignant trophoblastic cells. Biochem Biophys Res Commun 1977;78:591-5.
11. Kanduc D, Grazia di Corcia M, Lucchese A, Natale C. Enhanced expression of initiator tRNA(Met) in human gastric and colorectal carcinoma. Biochem Mol Biol Int 1997;43:1323-9.
12. Daly NL, Arvanitis DA, Fairley JA, Gse A, Natale C. Enhanced expression et al. Deregulation of RNA polymerase III transcription in cervical epithelium in response to high-risk human papillomavirus. Oncogene 2005;24:880-8.
13. Zhao KN, Liu WJ, Frazer IH. Codon usage bias and A+T content variation in human papillomavirus genomes. Virus Res 2003;98:95-104.
14. Day PM, Roden RB, Lowy DR, Schiller JT. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol 1998;72:142-50.
15. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-7.
16. Carter JJ, Yaegashi N, Jenison SA, Galloway DA. Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology 1991;182:513-21.
17. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995;206:126-35.
18. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997;71:2988-95.
19. Chen XS, Casini G, Harrison SC, Garcea RL. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol 2001;307:173-82.
20. Iyengar S, Shah KV, Kotloff KL, Ghim SJ, Viscidi RP. Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. Clin Diagn Lab Immunol 1996;3:733-9.
21. Disbrow GL, Sunitha I, Baker CC, Hanover J, Schlegel R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 2003;311:105-14.
22. Wang XM, Jansen KU, McClements WL. DNA replicative functions of highly-expressed, codon-optimized human papillomavirus proteins E1 and E2. J Virol Methods 2003;108:83-90.
23. Gornemann J, Hofmann TG, Will H, Müller M. Interaction of human papillomavirus type 16 L2 with cellular proteins: identification of novel nuclear body-associated proteins. Virology 2002;303:69-78.
24. Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 2004;78:12901-9.
25. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Müller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003;77:9211-20.
26. Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 2003;77:4928-37.
27. Leder C, Kleinschmidt JA, Wiethe C, Müller M. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 2001;75:9201-9.
28. Liu WJ, Gao F, Zhao KN, Zhao W, Fernando GJ, Thomas R et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 2002;301:43-52.
29. Steinberg T, Öhlschlager P, Sehr P, Osen W, Gissmann L. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine 2005;23:1149-57.
30. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004;321:205-16.
31. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004;78:751-7.
32. Favre M. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol 1975;15:1239-47.
33. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996;70:5875-83.
34. Kennedy IM, Haddow JK, Clements JB. A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J Virol 1991;65:2093-7.
35. Kennedy IM, Haddow JK, Clements JB. Analysis of human papillomavirus type 16 late mRNA 3′ processing signals in vitro and in vivo. J Virol 1990;64:1825-9.
36. Schwartz S. Regulation of human papillomavirus late gene expression. Ups J Med Sci 2000;105:171-92.
37. Collier B, Oberg D, Zhao X, Schwartz S. Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J Virol 2002;76:2739-52.
38. Rollman E, Arnheim L, Collier B, Oberg D, Hall H, Klingstrom J et al. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology 2004;322:182-9.
39. Zhou J, Liu WJ, Peng SW, Sun XY, Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol 1999;73:4972-82.
40. Ser(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes. Nucleic Acids Res 2004;32:4448-61.
41. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2001;20:862-9.
42. Moore RA, Santos EB, Nicholls PK, White KL, Anderson DM, Lloyd A et al. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles. Virology 2002;304:451-9.
43. Chen SL, Lee W, Hottes AK, Shapiro L, McAdams HH. Codon usage between genomes is constrained by genome-wide mutational processes. Proc Natl Acad Sci USA 2004;101:3480-5.
44. D'Onofrio G, Jabbari K, Musto H, Bernardi G. The correlation of protein hydropathy with the base composition of coding sequences. Gene 1999;238:3-14.
45. Karlin S, Bucher P. Correlation analysis of aminoacid usage in protein classes. Proc Natl Acad Sci USA 1992;89:12165-9.
46. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004;68:362-72.
47. Bravo IG, Alonso A, Auvinen E. Human papillomavirus type 16 E5 protein. Papillomavirus Report 2004;15:1-6.
48. Shepherd JCW. From primeval message to present-day gene. Cold Spring Harbor Symp Quant Biol 1982;47:1099-108.
49. Varenne S, Buc J, Lloures R, Ladzunski C. Translation is a non-uniform process: effect of tRNA availability on the rate of elongation of the nascent polypeptide chains. J Mol Biol 1984;180:549-76.
50. Dong H, Nilsson L, Kurland CG. Co-variation of tRNA abundance and codon usage in Escherichia coli at different growth rates. J Mol Biol 1996;209:65-77.
51. Rocha EPC. Codon usage bias from tRNA's point of view: redundancy, specialization, and efficient decoding for translation optimization. Genome Res 2004;14:2279-86.
52. Sharp PM, Matassi G. Codon usage and genome evolution. Curr Opin Genet Dev 1994;4:851-60.
53. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001;409:860-916.
54. Guthrie C, Abelson J. Organization and expression of tRNA genes in Saccharomyces cerevisiae. In: Strathern J, Broach J. (eds) The molecular biology of the yeast Saccharomyees: metabolism and gene expression. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1982; 487-528.
55. Archetti M. Selection on codon usage for error minimization at the protein level. J Mol Evol 2004;59:400-15.
56. Shadan FF, Villarreal LP. Coevolution of persistently infecting small DNA viruses and their hosts linked to host-interactive regulatory domains. Proc Natl Acad Sci USA 1993;90:4117-21.